Several prospective clinical trials have been conducted to determine the RR to EGFR-TKIs in Caucasian and in East Asian patients carrying EGFR somantic mutations [85-89]; these data suggest that EGFR-TKIs are highly active treatment for patients harbouring EGFR gene mutations; however, at this time there are no data from prospective randomized clinical trial which demonstrate a survival advantage for NSCLC patients with EGFR mutation treated with EGFR-TKIs. Here, EGFR is linked to non-small cell lung carcinoma.